GlassScriptPhysician profile
Gregory Shelton
NPI 1497958458
$3,165.11
in general payments reported to CMS, 2019-2025
28 companies · $447 in 2025
The $447 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $293 · 2021: $421 · 2022: $704 · 2023: $620 · 2024: $287 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $846.00 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Exeltis, USA INC. | $211.53 | 2019-2025 | Slynd |
| Myovant Sciences INC. | $195.50 | 2021-2022 | |
| Astellas Pharma US INC | $194.22 | 2022-2025 | Veozah, Myrbetriq |
| Medtronic, INC. | $175.98 | 2023-2025 | Venaseal, V-Loc 180 |
| Bayer Healthcare Pharmaceuticals INC. | $169.23 | 2019-2023 | |
| Hologic Sales and Service, LLC | $161.48 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Sumitomo Pharma America, INC. | $156.41 | 2023-2024 | Myfembree |
| Agile Therapeutics, INC. | $124.18 | 2021-2023 | Twirla |
| Organon LLC | $123.69 | 2021-2025 | Nexplanon |
| Coopersurgical, INC. | $118.13 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Renovia INC | $103.51 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $70.33 | 2023-2024 | |
| Exact Sciences Corporation | $67.10 | 2023-2025 | Cologuard Collection Kit |
| Sage Therapeutics, LLC | $66.53 | 2024-2025 | Zurzuvae |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.45 | 2019-2023 | Gardasil 9 |
| Pfizer INC. | $54.84 | 2023-2024 | |
| Medicem INC. | $51.92 | 2020-2022 | |
| Aspira Women'S Health INC | $36.12 | 2022-2024 | Ova1 |
| Avion Pharmaceuticals | $28.87 | 2020-2021 | |
| Smith+Nephew, INC. | $28.60 | 2024 | Pico 7 |
| Amgen INC. | $28.41 | 2023-2025 | Prolia, Evenity |
| Radius Health, INC. | $19.05 | 2019 | |
| Lupin INC. | $18.62 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.48 | 2025 | Unithroid |
| Evofem Biosciences, INC. | $13.55 | 2020 | |
| Therapeuticsmd, INC. | $12.01 | 2019 | |
| Allergan, INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Shelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.